IXIARO from Valneva SE - travel vaccine with a clear safety profile

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 17:25. Details in the imprint.

IXIARO is the kind of vaccine you remember from the travel clinic, the small clear vial that stands between your summer in rural Asia and a virus you never want to meet. The nurse snaps the syringe onto the needle, the alcohol swab feels cold on your skin, and in less than ten seconds the shot is done. No glamour, just a quiet, practical shield against Japanese encephalitis.

Where IXIARO is used

IXIARO from Valneva SE is a purified, inactivated vaccine against Japanese encephalitis, a mosquito-borne viral infection that can be fatal or leave lasting neurological damage. It is approved for adults and children from two months of age in Europe, the US and several other markets. Travel doctors like Hamburg-based specialist Dr. Anne Vogt use it routinely for patients heading to rural regions in Asia, especially when they plan extended stays or outdoor activities.

The vaccine is given in a two-dose primary series, typically on day zero and between day seven and 28, with a booster recommended for those who remain at risk. For the traveller, that means planning ahead: you feel the faint sting in the upper arm twice before departure, and then you mostly forget about it until you see rice fields and humid dusk air around you. Military organisations and NGOs also rely on IXIARO for personnel deployed to endemic regions, turning it into a B2B staple as much as a consumer travel product.

What the data say

According to Valneva, IXIARO showed high seroconversion rates in pivotal trials, with more than 96 percent of adult participants developing protective antibodies after the two-dose series. Follow-up data indicate persistence of immunity for several years, supported by booster dosing for ongoing exposure. The vaccine uses an inactivated whole-virus approach based on the SA14-14-2 strain, produced on Vero cells and formulated with aluminium hydroxide as adjuvant.

In everyday terms, that translates into a predictable experience at the clinic: most people report only mild injection-site pain or redness, similar to a standard travel shot. Specialist reviews, such as a summary from the US Centers for Disease Control and Prevention, classify IXIARO's safety profile as convincing, with serious adverse events rare and broadly comparable to other routine vaccines. For parents weighing risks before taking a child to Southeast Asia, that combination of efficacy and tolerability often becomes the decisive argument.

Pricing and availability

IXIARO is primarily a prescription product, supplied to travel clinics, hospitals and military medical services rather than sold over the counter. In Germany, private travellers usually pay for the vaccine themselves, with prices at clinics typically around 80 to 100 euros per dose depending on consultation fees. In the US, the product is marketed under the name Ixiaro and distributed through partners to travel health centers and the armed forces.

Valneva manufactures IXIARO in its facilities in Scotland and Austria, shipping batches worldwide subject to strict cold-chain requirements. That means the vial you see on the metal tray has travelled far at 2 to 8 degrees Celsius before reaching your arm. The company's latest annual report highlights IXIARO and related Japanese encephalitis vaccines as a steady revenue contributor in the travel and military segment, even as newer products move through the pipeline.

How it fits Valneva's strategy

CEO Thomas Lingelbach often cites travel vaccines such as IXIARO as the backbone that allows Valneva to invest in newer programs, ranging from chikungunya to Lyme disease. For investors this older portfolio is less glamorous than a headline-grabbing new launch, but its cash flows help smooth the ups and downs of development cycles. IXIARO has also positioned the company as a recognised specialist in vaccines against diseases that mainstream pharma tends to overlook.

Bottom line, IXIARO is a relatively quiet product that matters a lot internally. It does not trend on social media, but it fills planes and deployments with people whose risk has been sharply reduced. Valneva SE shares (ISIN FR0013280286) trade as ADRs on Nasdaq under the ticker VALN, giving international investors direct exposure to this travel-vaccine niche.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.